Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Capstar Special Acquisition Corp Cl A (CPSR)

Capstar Special Acquisition Corp Cl A (CPSR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 253,920
  • Shares Outstanding, K 34,500
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,220 K
  • 60-Month Beta 0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CPSR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.06 +21.45%
on 01/12/22
12.23 -39.82%
on 01/10/22
-2.58 (-25.96%)
since 12/13/21
3-Month
6.06 +21.45%
on 01/12/22
12.23 -39.82%
on 01/10/22
-2.63 (-26.33%)
since 10/13/21
52-Week
6.06 +21.45%
on 01/12/22
12.23 -39.82%
on 01/10/22
-2.86 (-27.98%)
since 01/13/21

Most Recent Stories

More News
PureTech Health plc – Half-Year Report

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its half-yearly results for the six months ended June 30, 2022. The following information will be filed...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
AKLI : 0.2331 (-6.01%)
GLS : 0.1586 (+0.38%)
DNAA : 14.07 (+47.02%)
RBLX : 34.66 (-0.89%)
CPSR : 7.36 (+9.85%)
KRTX : 329.83 (+0.03%)
VOR : 1.6700 (-4.02%)
PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis”),...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
GLS : 0.1586 (+0.38%)
CPSR : 7.36 (+9.85%)
PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE: GLS) (“Gelesis),...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
GLS : 0.1586 (+0.38%)
CPSR : 7.36 (+9.85%)
PureTech Announces Annual Results for Year Ended December 31, 2021

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
DNAA : 14.07 (+47.02%)
CPSR : 7.36 (+9.85%)
PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Gelesis, Inc. (“Gelesis”), the maker...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
CPSR : 7.36 (+9.85%)
Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar

Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) (“Capstar”)....

CPSR : 7.36 (+9.85%)
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
INGN : 6.65 (-5.67%)
CPSR : 7.36 (+9.85%)
Gelesis Adds Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee

Gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of Plenity®, announced the appointment of senior financial executive Ali Bauerlein to its Board of Directors....

INGN : 6.65 (-5.67%)
CPSR : 7.36 (+9.85%)
Have Your Cake and Eat It Too: Plenity® Creates Edible Dessert Billboard to Challenge Overly Restrictive Dieting Assumptions

Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, has created an edible billboard in New York City’s Astor Place to challenge the idea that people can’t eat the foods they...

CPSR : 7.36 (+9.85%)
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Gelesis, Inc. (“Gelesis”) announced...

PRTC : 27.48 (+5.09%)
PRTC.LN : 211.500 (-0.47%)
CPSR : 7.36 (+9.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Capstar Special Purpose Acquisition Corp. entered into a definitive business combination agreement with Gelesis Inc.

See More

Key Turning Points

3rd Resistance Point 9.00
2nd Resistance Point 8.24
1st Resistance Point 7.80
Last Price 7.36
1st Support Level 6.60
2nd Support Level 5.84
3rd Support Level 5.40

See More

52-Week High 12.23
Fibonacci 61.8% 9.87
Fibonacci 50% 9.14
Fibonacci 38.2% 8.42
Last Price 7.36
52-Week Low 6.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar